Core Viewpoint - A class action securities lawsuit has been filed against Skye Bioscience, Inc. due to alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Skye Bioscience's lead product candidate, nimacimab, was less effective than previously represented, leading to overstated clinical, regulatory, and commercial prospects [2]. - Defendants are accused of making materially false and misleading public statements regarding the effectiveness and prospects of nimacimab [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Skye Bioscience, Inc. securities during the Class Period from November 4, 2024, to October 3, 2025, of the January 16, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Skye securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by January 16, 2026, to serve as lead plaintiff, representing other class members [2]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Skye's business and prospects, specifically about the effectiveness of nimacimab and its clinical, regulatory, and commercial prospects [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [3]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Skye Bioscience, Inc. regarding a class action lawsuit due to alleged misleading statements about the company's lead product candidate, nimacimab, which was claimed to be less effective than represented [1][3]. Group 1: Class Action Details - The class period for the lawsuit is from November 4, 2024, to October 3, 2025 [3]. - Allegations include that the defendants made materially false and misleading statements about nimacimab's effectiveness and its clinical, regulatory, and commercial prospects [3]. - The deadline for shareholders to register for the class action is January 16, 2026, and there is no cost to participate [4]. Group 2: Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to deceit and misleading practices by companies [5]. - The firm emphasizes the importance of responsible business practices and good corporate citizenship [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Skye Bioscience, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on January 16, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Skye securities between November 4, 2024, and October 3, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2]. - The deadline to move the Court to serve as lead plaintiff is January 16, 2026, with the lead plaintiff representing other class members in the litigation [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements about Skye's business and prospects, specifically regarding the effectiveness of nimacimab [4]. - It is claimed that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to materially false public statements by the defendants [4]. - The lawsuit asserts that investors suffered damages when the true details about the company's prospects became known [4].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. on behalf of investors who acquired Skye securities during the specified Class Period, alleging misleading information regarding the company's lead candidate, nimacimab [1][2]. Company Overview - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on developing treatments for obesity and metabolic diseases [2]. Legal Proceedings - The lawsuit claims that throughout the Class Period, the defendants misled investors about the prospects of nimacimab [2]. - Investors are given a deadline of January 16, 2026, to seek appointment as lead plaintiff representatives of the class [2]. Stock Performance - On October 6, 2025, Skye published topline findings from its 26-week Phase 2a CBeyond trial of nimacimab, which failed to meet its primary weight-loss endpoint compared to placebo. Following this announcement, Skye's stock price dropped by $2.85 per share, approximately 60%, closing at $1.90 [3].

Core Viewpoint - A class action securities lawsuit has been filed against Skye Bioscience, Inc. due to alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Skye Bioscience's lead product candidate, nimacimab, was less effective than previously represented, leading to overstated clinical, regulatory, and commercial prospects [2]. - Defendants are accused of making materially false and misleading public statements regarding the effectiveness and prospects of nimacimab [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from November 4, 2024, to October 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Skye securities during the specified Class Period [2]. - The complaint alleges that the defendants made materially false and misleading statements regarding Skye's business, operations, and prospects [3]. - Specific allegations include that nimacimab was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [8]. Group 2: Investor Participation - Investors who suffered losses in Skye have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [4]. Group 3: Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [5]. - The firm emphasizes restoring investor capital and ensuring corporate accountability to maintain market integrity [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Bioscience, Inc. due to allegations of violations of federal securities laws related to misleading statements about the effectiveness of its drug nimacimab [2][4]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in Skye between November 4, 2024, and October 3, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][6]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [6]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives made false and misleading statements regarding the effectiveness of nimacimab, overstating its clinical and commercial prospects [4]. - On October 6, 2025, Skye announced that its nimacimab did not achieve the primary endpoint of weight loss compared to placebo, leading to a significant stock price drop of 60%, closing at $1.90 per share [5]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. - The firm is actively seeking information regarding Skye's conduct from whistleblowers, former employees, and shareholders [7].

Core Viewpoint - A class action securities lawsuit has been filed against Skye Bioscience, Inc. due to alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that the defendants made false statements regarding the effectiveness of the Company's lead product candidate, nimacimab, which was claimed to be less effective than represented [2]. - It is asserted that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to materially false and misleading public statements by the defendants [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - The complaint against Skye Bioscience alleges that the company and its executives misled investors regarding the effectiveness and prospects of nimacimab, leading to significant stock price decline following the release of disappointing clinical trial results [2][3]. Group 1: Allegations and Impact - The complaint claims that nimacimab was less effective than previously communicated, resulting in overstated clinical, regulatory, and commercial prospects [2]. - Following the announcement of the Phase 2a study results, Skye's stock price dropped by $2.85 per share, or 60%, closing at $1.90 per share on October 6, 2025 [3]. Group 2: Legal Proceedings - The lead plaintiff in the class action is the investor with the largest financial interest, who will oversee the litigation on behalf of the class [4]. - Any member of the putative class can apply to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [4]. Group 3: Call for Information - The law firm Faruqi & Faruqi encourages individuals with information regarding Skye's conduct to come forward, including whistleblowers and former employees [5].